RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Voor het derde jaar op rij is Quintiles als brancheleider genoemd in Fase I-diensten door respondenten in het 2015 CRO Quality Benchmarking – Phase I Service Providers rapport van Industry Standard Research (ISR). Quintiles werd ook genoemd als de geprefereerde Fase I-dienstverlener in ISR’s enquête van beleidsmakers in de biofarmaceutische industrie in Noord-Amerika, Europa en Azië.
“We voelen ons vereerd dat we opnieuw zijn genoemd als industrieleider in Fase I-diensten en als geprefereerde Fase I-dienstverlener in ISR’s rapport over 2015”, zei Mary Westrick, Ph. D., vicepresident vroege klinische ontwikkeling van Quintiles. “Ik geloof dat de wetenschappelijke expertise en klinische ervaring van de staf van Quintiles en onze mogelijkheid om geïntegreerde oplossingen te bieden onze klanten helpen betere beslissingen te maken tijdens de vroege klinische ontwikkeling.”
Quintiles Recognized as Phase I Services Leader for Third Consecutive Year
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– For the third year in a row, Quintiles has been named the industry leader in Phase I services according to respondents in Industry Standard Research’s (ISR) 2015 CRO Quality Benchmarking – Phase I Service Providers report. Quintiles also was identified as the most preferred Phase I service provider based on ISR’s survey of biopharmaceutical industry decision-makers across North America, Europe and Asia.
“We are honored to be recognized once again as the industry leader in Phase I services and most preferred Phase I service provider in ISR’s 2015 report,” said Mary Westrick, Ph.D., vice president, Early Clinical Development at Quintiles. “I believe that the scientific expertise and clinical experience of Quintiles’ staff, as well as our ability to offer integrated solutions, helps our customers make better decisions during early clinical development.”
Survey respondents also identified Quintiles as the “best service provider for differentiation” based on service quality, with particular strengths in data quality, financial strength/stability, and local market/regulatory knowledge.
“I believe the ISR report reflects the effectiveness of our approach to proactive quality management as well as the importance of our unwavering commitment to the highest quality standards,” said Westrick. “Our approach combines Failure Mode and Effects Analysis (FMEA) as well as quality audit findings to identify potential risks early and implement mitigation measures before studies even begin.”
A pioneer in early clinical development approaches, Quintiles helps the biopharmaceutical industry design and deliver standard safety studies as well as complex, multi-site and patient-focused early clinical trials. Leveraging expertise across its global enterprise, Quintiles delivers accurate data and precise insights that inform strategic go/no-go decisions early.
The results of this Phase I study follow Quintiles’ recent recognition in another ISR report that noted the company was once again the industry leader and preferred provider in Phase IV services – a designation it also received for the third consecutive year.
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.